Abatacept & Shingles Vaccine: Reduced Response, More Reactions in RA Patients

Rheumatoid arthritis (RA) patients taking abatacept, a medication used to suppress the immune system, may experience a reduced response to the recombinant zoster vaccine (RZV), commonly known as Shingrix, according to recent research. Although the vaccine remains safe for this population, the study indicates a diminished ability to develop protective antibodies and cellular immunity following vaccination. This finding underscores the complexities of vaccination in individuals with autoimmune conditions and those on immunosuppressive therapies.

Study Details and Findings

The research, published in PubMed and Annals of the Rheumatic Diseases, involved 70 participants with RA, randomized to receive either two doses of RZV or a placebo. Researchers assessed immune responses 12 weeks after the second dose, focusing on the development of antibodies and the activation of immune cells. The primary goal was to evaluate both the safety and how well the vaccine worked in people with RA who were also using abatacept.

The results showed that only 42.3% of those receiving RZV developed a four-fold increase in antibodies against the varicella-zoster virus (the virus that causes shingles), a key indicator of humoral response. Cellular immune responses, measured by the activation of interferon gamma and interleukin-2 producing cells, were even lower, observed in only 10.2% of vaccinated participants. The geometric mean fold rise in both cellular and humoral responses was also significantly reduced compared to what is typically seen in healthy individuals. However, the study did not find a significant difference in the rate of RA flares between the vaccinated and placebo groups, with approximately 68% of the RZV group and 64% of the placebo group experiencing a flare.

Six serious adverse events were reported during the 52-week study period, but these were not definitively linked to the vaccine. Injection-site reactions were more common in the RZV group, but were generally mild to moderate in severity. Medscape Medical News reports that these findings suggest the vaccine is safe, but less effective in this patient population.

Understanding Abatacept and Immune Response

Abatacept works by interfering with the activation of T cells, a type of immune cell crucial for fighting off infections. It specifically targets the interaction between T cells and antigen-presenting cells, thereby modulating the immune response. This mechanism of action, while effective in managing RA, can also dampen the immune system’s ability to respond to vaccines. The study confirms that abatacept’s immunosuppressive effects can indeed attenuate the immune response to the RZV, potentially leaving patients less protected against shingles.

Shingles and the Importance of Vaccination

Shingles, or herpes zoster, is a painful rash caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. After having chickenpox, the virus remains dormant in nerve cells. As people age, or if their immune system is weakened, the virus can reactivate, causing shingles. The condition is characterized by a painful, blistering rash that typically appears on one side of the body. Complications can include postherpetic neuralgia (PHN), a chronic nerve pain that can persist for months or even years after the rash has healed.

Vaccination is the most effective way to prevent shingles and its complications. The RZV, Shingrix, is a highly effective vaccine recommended for adults aged 50 years and older, even if they have had shingles before. It is also recommended for adults with certain medical conditions that weaken the immune system, including RA. However, the effectiveness of the vaccine may be reduced in individuals taking immunosuppressive medications like abatacept.

Implications for Clinical Practice and Future Research

The findings from this study have important implications for clinical practice. Healthcare providers should be aware of the potentially reduced vaccine response in RA patients taking abatacept and counsel them accordingly. While vaccination is still recommended, patients should understand that they may not achieve the same level of protection as those not on immunosuppressive therapy.

Researchers suggest exploring strategies to optimize vaccine response in this population. One potential approach is to temporarily hold abatacept around the time of vaccination, although this requires careful consideration of the risks and benefits, and should only be done under the guidance of a rheumatologist. Further studies are needed to determine the optimal timing and duration of abatacept interruption, if any, to maximize vaccine effectiveness. The study authors also note the need for ongoing surveillance to monitor the incidence of shingles and the effectiveness of vaccination in RA patients on abatacept.

What Comes Next: Ongoing Evaluation and Guidance Updates

The study’s findings will likely prompt further investigation into vaccination strategies for individuals with autoimmune diseases on immunosuppressive therapies. Rheumatology and infectious disease specialists will continue to evaluate the data and refine vaccination recommendations. Public health agencies, such as the Centers for Disease Control and Prevention (CDC), will monitor shingles incidence rates and vaccine effectiveness in this population to inform future guidance updates. It’s important for individuals with RA and their healthcare providers to stay informed about the latest recommendations regarding shingles vaccination.